TY - CHAP
T1 - The therapeutic potential of nanoscale sphingolipid technologies
AU - Hankins, Jody L.
AU - Doshi, Ushma A.
AU - Haakenson, Jeremy K.
AU - Young, Megan M.
AU - Barth, Brian M.
AU - Kester, Mark
N1 - Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2013
Y1 - 2013
N2 - Nanotechnologies, while small in size, widen the scope of drug delivery options for compounds with problematic pharmacokinetics, such as bioactive sphingolipids. We describe the development of historical sphingolipid nanotechnologies, such as nanoliposomes, and project future uses for a broad repertoire of nanoscale sphingolipid therapy formulations. In particular, we describe sphingo-nanotherapies for treatment of cancer, inflammatory disease, and cardiovascular disease. We conclude with a discussion of the challenges associated with regulatory approval, scale-up, and development of these nanotechnology therapies for clinical applications.
AB - Nanotechnologies, while small in size, widen the scope of drug delivery options for compounds with problematic pharmacokinetics, such as bioactive sphingolipids. We describe the development of historical sphingolipid nanotechnologies, such as nanoliposomes, and project future uses for a broad repertoire of nanoscale sphingolipid therapy formulations. In particular, we describe sphingo-nanotherapies for treatment of cancer, inflammatory disease, and cardiovascular disease. We conclude with a discussion of the challenges associated with regulatory approval, scale-up, and development of these nanotechnology therapies for clinical applications.
UR - http://www.scopus.com/inward/record.url?scp=84880445857&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84880445857&partnerID=8YFLogxK
U2 - 10.1007/978-3-7091-1368-4_11
DO - 10.1007/978-3-7091-1368-4_11
M3 - Chapter
C2 - 23579457
AN - SCOPUS:84880445857
SN - 9783709113677
T3 - Handbook of Experimental Pharmacology
SP - 197
EP - 210
BT - Sphingolipids
PB - Springer Science and Business Media, LLC
ER -